E
Portage Biotech Inc.
PRTG
$6.98
-$1.28-15.50%
E
Sell
8/15/2024Upgraded
Portage Biotech Inc. (PRTG) was upgraded to E+ from E on 8/15/2024 due to an increase in the total return index and volatility index.
Portage Biotech Inc. (PRTG) was upgraded to E+ from E on 8/15/2024 due to an increase in the total return index and volatility index.
E
Sell
7/25/2024Downgrade
Portage Biotech Inc. (PRTG) was downgraded to E from E+ on 7/25/2024 due to a decline in the total return index and volatility index.
Portage Biotech Inc. (PRTG) was downgraded to E from E+ on 7/25/2024 due to a decline in the total return index and volatility index.
E
Sell
6/4/2024Upgraded
Portage Biotech Inc. (PRTG) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
Portage Biotech Inc. (PRTG) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
E
Sell
5/17/2024Downgrade
Portage Biotech Inc. (PRTG) was downgraded to E from E+ on 5/17/2024 due to a decline in the volatility index.
Portage Biotech Inc. (PRTG) was downgraded to E from E+ on 5/17/2024 due to a decline in the volatility index.
E
Sell
5/2/2024Upgraded
Portage Biotech Inc. (PRTG) was upgraded to E+ from E on 5/2/2024 due to an increase in the volatility index.
Portage Biotech Inc. (PRTG) was upgraded to E+ from E on 5/2/2024 due to an increase in the volatility index.
E
Sell
4/12/2024Downgrade
Portage Biotech Inc. (PRTG) was downgraded to E from E+ on 4/12/2024 due to a noticeable decline in the volatility index, solvency index and total return index.
Portage Biotech Inc. (PRTG) was downgraded to E from E+ on 4/12/2024 due to a noticeable decline in the volatility index, solvency index and total return index.
E
Sell
3/20/2023Downgrade
Portage Biotech Inc. (PRTG) was downgraded to E+ from D- on 3/20/2023 due to a decline in the volatility index and total return index.
Portage Biotech Inc. (PRTG) was downgraded to E+ from D- on 3/20/2023 due to a decline in the volatility index and total return index.
D
Sell
3/3/2023Downgrade
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 3/3/2023 due to a major decline in the growth index and solvency index. Earnings per share declined from -$0.06 to -$0.44, the quick ratio declined from 10.67 to 5.49, and EBIT declined 33.97% from -$3.55M to -$4.76M.
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 3/3/2023 due to a major decline in the growth index and solvency index. Earnings per share declined from -$0.06 to -$0.44, the quick ratio declined from 10.67 to 5.49, and EBIT declined 33.97% from -$3.55M to -$4.76M.
D
Sell
2/23/2023Upgraded
Portage Biotech Inc. (PRTG) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
Portage Biotech Inc. (PRTG) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and volatility index.
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
9/2/2022Upgraded
Portage Biotech Inc. (PRTG) was upgraded to D from D- on 9/2/2022 due to a substantial increase in the growth index. Earnings per share increased from -$0.5484 to -$0.13, EBIT increased 4.86% from -$4.3M to -$4.09M, and operating cash flow increased 3.33% from -$2.25M to -$2.18M.
Portage Biotech Inc. (PRTG) was upgraded to D from D- on 9/2/2022 due to a substantial increase in the growth index. Earnings per share increased from -$0.5484 to -$0.13, EBIT increased 4.86% from -$4.3M to -$4.09M, and operating cash flow increased 3.33% from -$2.25M to -$2.18M.
D
Sell
8/22/2022Downgrade
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 8/22/2022 due to a decline in the total return index and volatility index.
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 8/22/2022 due to a decline in the total return index and volatility index.
D
Sell
8/4/2022Upgraded
Portage Biotech Inc. (PRTG) was upgraded to D from D- on 8/4/2022 due to an increase in the total return index and growth index.
Portage Biotech Inc. (PRTG) was upgraded to D from D- on 8/4/2022 due to an increase in the total return index and growth index.
D
Sell
3/21/2022Downgrade
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 3/21/2022 due to a major decline in the total return index, solvency index and volatility index.
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 3/21/2022 due to a major decline in the total return index, solvency index and volatility index.
D
Sell
11/23/2021Upgraded
Portage Biotech Inc. (PRTG) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index and total return index.
Portage Biotech Inc. (PRTG) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index and total return index.
D
Sell
11/8/2021Downgrade
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index, growth index and valuation index. Operating cash flow declined 72.3% from -$917 to -$1.58M.
Portage Biotech Inc. (PRTG) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index, growth index and valuation index. Operating cash flow declined 72.3% from -$917 to -$1.58M.
D
Sell
7/30/2021Downgrade
Portage Biotech Inc. (PRTG) was downgraded to D from D+ on 7/30/2021 due to a substantial decline in the growth index, solvency index and total return index. EBIT declined 1,014.61% from -$801 to -$8.93M, earnings per share declined from -$0.1 to -$0.9528, and the quick ratio declined from 3.16 to 0.86.
Portage Biotech Inc. (PRTG) was downgraded to D from D+ on 7/30/2021 due to a substantial decline in the growth index, solvency index and total return index. EBIT declined 1,014.61% from -$801 to -$8.93M, earnings per share declined from -$0.1 to -$0.9528, and the quick ratio declined from 3.16 to 0.86.
D
Sell
7/21/2021Upgraded
Portage Biotech Inc. (PRTG) was upgraded to D+ from D on 7/21/2021 due to an increase in the valuation index.
Portage Biotech Inc. (PRTG) was upgraded to D+ from D on 7/21/2021 due to an increase in the valuation index.
D
Sell
6/22/2021Downgrade
Portage Biotech Inc. (PRTG) was downgraded to D from D+ on 6/22/2021 due to a decline in the valuation index.
Portage Biotech Inc. (PRTG) was downgraded to D from D+ on 6/22/2021 due to a decline in the valuation index.
D
Sell
6/7/2021Upgraded
Portage Biotech Inc. (PRTG) was upgraded to D+ from D on 6/7/2021 due to a substantial increase in the growth index, solvency index and valuation index. The quick ratio increased from 1 to 2.74, operating cash flow increased 57.88% from -$1.89M to -$794, and earnings per share increased from -$0.2101 to -$0.1.
Portage Biotech Inc. (PRTG) was upgraded to D+ from D on 6/7/2021 due to a substantial increase in the growth index, solvency index and valuation index. The quick ratio increased from 1 to 2.74, operating cash flow increased 57.88% from -$1.89M to -$794, and earnings per share increased from -$0.2101 to -$0.1.
D
Sell
6/4/2020Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D from D+ on 6/4/2020 due to a large decline in the growth index, solvency index and valuation index.
Portage Biotech Inc. (PTGEF) was downgraded to D from D+ on 6/4/2020 due to a large decline in the growth index, solvency index and valuation index.
D
Sell
3/23/2020Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to D+ from D on 3/23/2020 due to a noticeable increase in the total return index and growth index. Earnings per share increased from -$0.0012 to -$0.0003, operating cash flow increased 47.71% from -$1.24M to -$650, and EBIT increased 28.82% from -$1.52M to -$1.08M.
Portage Biotech Inc. (PTGEF) was upgraded to D+ from D on 3/23/2020 due to a noticeable increase in the total return index and growth index. Earnings per share increased from -$0.0012 to -$0.0003, operating cash flow increased 47.71% from -$1.24M to -$650, and EBIT increased 28.82% from -$1.52M to -$1.08M.
D
Sell
1/10/2020Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D from D+ on 1/10/2020 due to a decline in the total return index and volatility index.
Portage Biotech Inc. (PTGEF) was downgraded to D from D+ on 1/10/2020 due to a decline in the total return index and volatility index.
D
Sell
1/9/2020Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D+ from C- on 1/9/2020 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 26.97% from -$979 to -$1.24M.
Portage Biotech Inc. (PTGEF) was downgraded to D+ from C- on 1/9/2020 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 26.97% from -$979 to -$1.24M.
C
Hold
9/21/2018Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to C- from D+ on 9/21/2018 due to an increase in the volatility index and total return index.
Portage Biotech Inc. (PTGEF) was upgraded to C- from D+ on 9/21/2018 due to an increase in the volatility index and total return index.
D
Sell
9/4/2018Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D+ from C- on 9/4/2018 due to a noticeable decline in the growth index and total return index. Earnings per share declined from $0.4341 to -$0.0008.
Portage Biotech Inc. (PTGEF) was downgraded to D+ from C- on 9/4/2018 due to a noticeable decline in the growth index and total return index. Earnings per share declined from $0.4341 to -$0.0008.
C
Hold
8/3/2018Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to C- from D on 8/3/2018 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 35,645.87% from -$351 to $124.77M, earnings per share increased from -$0.0013 to $0.4369, and operating cash flow increased 41.6% from -$363 to -$212.
Portage Biotech Inc. (PTGEF) was upgraded to C- from D on 8/3/2018 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 35,645.87% from -$351 to $124.77M, earnings per share increased from -$0.0013 to $0.4369, and operating cash flow increased 41.6% from -$363 to -$212.
D
Sell
5/7/2018Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 5/7/2018 due to an increase in the volatility index.
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 5/7/2018 due to an increase in the volatility index.
D
Sell
4/11/2018Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D- from D on 4/11/2018 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 1,371.46 to 81.72.
Portage Biotech Inc. (PTGEF) was downgraded to D- from D on 4/11/2018 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 1,371.46 to 81.72.
D
Sell
1/10/2018Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D from D+ on 1/10/2018 due to a large decline in the total return index and volatility index.
Portage Biotech Inc. (PTGEF) was downgraded to D from D+ on 1/10/2018 due to a large decline in the total return index and volatility index.
D
Sell
11/17/2017Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D+ from C on 11/17/2017 due to a significant decline in the valuation index, growth index and total return index. EBIT declined 2.43% from -$325.1 to -$333, and operating cash flow declined 1.46% from -$247.2 to -$250.8.
Portage Biotech Inc. (PTGEF) was downgraded to D+ from C on 11/17/2017 due to a significant decline in the valuation index, growth index and total return index. EBIT declined 2.43% from -$325.1 to -$333, and operating cash flow declined 1.46% from -$247.2 to -$250.8.
C
Hold
3/21/2017Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to C from C- on 3/21/2017 due to a substantial increase in the total return index, efficiency index and volatility index.
Portage Biotech Inc. (PTGEF) was upgraded to C from C- on 3/21/2017 due to a substantial increase in the total return index, efficiency index and volatility index.
C
Hold
12/23/2016Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to C- from D+ on 12/23/2016 due to a large increase in the total return index and volatility index.
Portage Biotech Inc. (PTGEF) was upgraded to C- from D+ on 12/23/2016 due to a large increase in the total return index and volatility index.
D
Sell
11/25/2016Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to D+ from D on 11/25/2016 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 1,349.68% from -$2.71M to $33.86M, earnings per share increased from -$0.0107 to $0.13, and total capital increased 202.07% from $15.11M to $45.65M.
Portage Biotech Inc. (PTGEF) was upgraded to D+ from D on 11/25/2016 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 1,349.68% from -$2.71M to $33.86M, earnings per share increased from -$0.0107 to $0.13, and total capital increased 202.07% from $15.11M to $45.65M.
D
Sell
11/11/2016Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 11/11/2016 due to an increase in the volatility index, total return index and valuation index.
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 11/11/2016 due to an increase in the volatility index, total return index and valuation index.
D
Sell
3/11/2016Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. EBIT declined 215.34% from -$1.53M to -$4.83M, and earnings per share declined from -$0.0041 to -$0.0112.
Portage Biotech Inc. (PTGEF) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. EBIT declined 215.34% from -$1.53M to -$4.83M, and earnings per share declined from -$0.0041 to -$0.0112.
D
Sell
6/22/2015Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 6/22/2015 due to a substantial increase in the volatility index and total return index.
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 6/22/2015 due to a substantial increase in the volatility index and total return index.
D
Sell
6/5/2015Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D- from D on 6/5/2015 due to a decline in the growth index and valuation index. Operating cash flow declined 44.02% from -$784.6 to -$439.2, earnings per share declined from -$0.004 to -$0.0031, and EBIT declined 7.47% from -$952.1 to -$881.
Portage Biotech Inc. (PTGEF) was downgraded to D- from D on 6/5/2015 due to a decline in the growth index and valuation index. Operating cash flow declined 44.02% from -$784.6 to -$439.2, earnings per share declined from -$0.004 to -$0.0031, and EBIT declined 7.47% from -$952.1 to -$881.
D
Sell
2/10/2015Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 2/10/2015 due to an increase in the valuation index.
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 2/10/2015 due to an increase in the valuation index.
D
Sell
1/6/2015Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to D- from D on 1/6/2015 due to a decline in the valuation index.
Portage Biotech Inc. (PTGEF) was downgraded to D- from D on 1/6/2015 due to a decline in the valuation index.
D
Sell
12/3/2014Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 12/3/2014 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 105.23% from -$382.3 to -$784.6.
Portage Biotech Inc. (PTGEF) was upgraded to D from D- on 12/3/2014 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 105.23% from -$382.3 to -$784.6.
D
Sell
8/6/2014Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to D- from E on 8/6/2014 due to an increase in the volatility index.
Portage Biotech Inc. (PTGEF) was upgraded to D- from E on 8/6/2014 due to an increase in the volatility index.
E
Sell
7/11/2014Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to E from E+ on 7/11/2014 due to a decline in the valuation index.
Portage Biotech Inc. (PTGEF) was downgraded to E from E+ on 7/11/2014 due to a decline in the valuation index.
E
Sell
5/7/2014Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to E+ from E on 5/7/2014 due to an increase in the valuation index.
Portage Biotech Inc. (PTGEF) was upgraded to E+ from E on 5/7/2014 due to an increase in the valuation index.
E
Sell
4/22/2014Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to E from E+ on 4/22/2014 due to a decline in the valuation index.
Portage Biotech Inc. (PTGEF) was downgraded to E from E+ on 4/22/2014 due to a decline in the valuation index.
E
Sell
4/7/2014Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to E+ from E on 4/7/2014 due to an increase in the valuation index.
Portage Biotech Inc. (PTGEF) was upgraded to E+ from E on 4/7/2014 due to an increase in the valuation index.
E
Sell
3/12/2014Upgraded
Portage Biotech Inc. (PTGEF) was upgraded to E from E- on 3/12/2014 due to an increase in the growth index, solvency index and efficiency index. Total capital increased 30.88% from $3.25M to $4.25M.
Portage Biotech Inc. (PTGEF) was upgraded to E from E- on 3/12/2014 due to an increase in the growth index, solvency index and efficiency index. Total capital increased 30.88% from $3.25M to $4.25M.
E
Sell
2/28/2014Downgrade
Portage Biotech Inc. (PTGEF) was downgraded to E- from E on 2/28/2014 due to a decline in total return and stability.
Portage Biotech Inc. (PTGEF) was downgraded to E- from E on 2/28/2014 due to a decline in total return and stability.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
